Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study

Non-alcoholic fatty liver disease (NAFLD) and atherosclerosis-related cardiovascular diseases (CVD) share common metabolic pathways. We explored the association between three NAFLD-associated single nucleotide polymorphisms (SNPs) rs738409, rs10401969, and rs1260326 with sub-clinical atherosclerosis estimated by the carotid intima-media thickness (c-IMT) and the inter-adventitia common carotid artery diameter (ICCAD) in patients free from clinically overt NAFLD and CVD. The study population is the IMPROVE, a multicenter European study (n = 3711). C-IMT measures and ICCAD were recorded using a standardized protocol. Linear regression with an additive genetic model was used to test for association of the three SNPs with c-IMT and ICCAD. In secondary analyses, the association of the three SNPs with c-IMT and ICCAD was tested after stratification by alanine aminotransferase levels (ALT). No associations were found between rs738409, rs1260326, rs10401969, and c-IMT or ICCAD. Rs738409-G and rs10401969-C were associated with ALT levels (p < 0.001). In patients with ALT levels above 28 U/L (highest quartile), we observed an association between rs10401969-C and c-IMT measures of c-IMTmax and c-IMTmean-max (p = 0.018 and 0.021, respectively). In conclusion, NAFLD-associated SNPs do not associate with sub-clinical atherosclerosis measures. However, our results suggest a possible mediating function of impaired liver function on atherosclerosis development.

[1]  A. Tierney,et al.  Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review. , 2019, Nutrition reviews.

[2]  D. Dumitrascu,et al.  Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review , 2019, Front. Med..

[3]  M. Budoff,et al.  Nonalcoholic Fatty Liver Disease Is Associated With Arterial Distensibility and Carotid Intima-Media Thickness: (from the Multi-Ethnic Study of Atherosclerosis). , 2019, The American journal of cardiology.

[4]  T. Lehtimäki,et al.  NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects , 2018, Human molecular genetics.

[5]  B. Nordestgaard,et al.  Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals , 2018, European heart journal.

[6]  J. Fragoso,et al.  Association of the I148M/PNPLA3 (rs738409) polymorphism with premature coronary artery disease, fatty liver, and insulin resistance in type 2 diabetic patients and healthy controls. The GEA study. , 2017, Immunobiology.

[7]  G. Sood,et al.  Non-alcoholic fatty liver disease and cardiovascular risk , 2017, World journal of gastrointestinal pathophysiology.

[8]  A. Morris,et al.  Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease , 2017, PLoS genetics.

[9]  C. Catalano,et al.  Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage. , 2017, Atherosclerosis.

[10]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  A. Lonardo,et al.  Non-alcoholic fatty liver disease and risk of cardiovascular disease. , 2016, Metabolism: clinical and experimental.

[13]  E. Schuetz,et al.  SUGP1 is a novel regulator of cholesterol metabolism , 2016, Human molecular genetics.

[14]  A. Vigano,et al.  Psoas Muscle Area and All-Cause Mortality After Transcatheter Aortic Valve Replacement: The Montreal-Munich Study. , 2016, The Canadian journal of cardiology.

[15]  K. Hong,et al.  The dietary monounsaturated to saturated fatty acid ratio modulates the genetic effects of GCKR on serum lipid levels in children. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[16]  Peter Scarborough,et al.  Cardiovascular disease in Europe--epidemiological update 2015. , 2015, European heart journal.

[17]  S. Romeo,et al.  Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis , 2015, BioMed research international.

[18]  E. Speliotes,et al.  TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? , 2015, Gastroenterology.

[19]  S. Humphries,et al.  Analysis of the Role of Interleukin 6 Receptor Haplotypes in the Regulation of Circulating Levels of Inflammatory Biomarkers and Risk of Coronary Heart Disease , 2015, PloS one.

[20]  N. Sattar,et al.  Non-alcoholic fatty liver disease , 2014, BMJ : British Medical Journal.

[21]  He Zhang,et al.  Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk , 2014, Nature Genetics.

[22]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[23]  T. Ando,et al.  Association of the GCKR rs780094 polymorphism with metabolic traits including carotid intima-media thickness in Japanese community-dwelling men, but not in women , 2014, Clinical chemistry and laboratory medicine.

[24]  M. Al-mallah,et al.  A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? , 2013, Atherosclerosis.

[25]  M. Bernardi,et al.  Interactions of the heart and the liver. , 2013, European heart journal.

[26]  L. N. Valenti,et al.  PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease , 2013, PloS one.

[27]  Sonia Shah,et al.  Identification of the BCAR1-CFDP1-TMEM170A Locus as a Determinant of Carotid Intima-Media Thickness and Coronary Artery Disease Risk , 2012, Circulation. Cardiovascular genetics.

[28]  Enzo Grossi,et al.  Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) study. , 2012, Journal of the American College of Cardiology.

[29]  E. Bonora,et al.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD , 2012, Nature Reviews Gastroenterology &Hepatology.

[30]  Hongyu Zhao,et al.  Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents , 2012, Hepatology.

[31]  F. Collins,et al.  Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk , 2011, Diabetologia.

[32]  B. Nordestgaard,et al.  TRIB1 and GCKR Polymorphisms, Lipid Levels, and Risk of Ischemic Heart Disease in the General Population , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[33]  B. Melegh,et al.  GCKR gene functional variants in type 2 diabetes and metabolic syndrome: do the rare variants associate with increased carotid intima-media thickness? , 2010, Cardiovascular diabetology.

[34]  S. Park,et al.  Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis. , 2010, Diabetes research and clinical practice.

[35]  S. Humphries,et al.  Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a European population: the IMPROVE study. , 2010, European heart journal.

[36]  R. Farah,et al.  Presence of coronary plaques in patients with nonalcoholic fatty liver disease. , 2010, Radiology.

[37]  A. Craxì,et al.  Non-alcoholic fatty liver disease pathogenesis: the present and the future. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[38]  F. Kronenberg,et al.  A common variant in the adiponutrin gene influences liver enzyme values , 2009, Journal of Medical Genetics.

[39]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[40]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[41]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[42]  K. Pietiläinen,et al.  Liver fat in the metabolic syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[43]  L. Bouter,et al.  Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. , 2007, Atherosclerosis.

[44]  G. Marchesini,et al.  Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease , 2005, Hepatology.

[45]  Zhi-Sheng Jiang,et al.  TM6SF2: A novel target for plasma lipid regulation. , 2018, Atherosclerosis.

[46]  Peter Scarborough,et al.  Cardiovascular disease in Europe 2015: epidemiological update. , 2015, European heart journal.

[47]  L. N. Valenti,et al.  Carotid artery intima-media thickness in nonalcoholic fatty liver disease. , 2008, The American journal of medicine.